Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.66 |
| ▸ | APP | P05067 | 2/20 | 0.66 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.62 |
| ▸ | BCHE | P06276 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23987 | 0.92 | NR4A2 (0.60) | MAOBAPPNR4A2BCHEMAOA | |
| SCHEMBL11857425 | 0.92 | MAOB (0.62) | MAOBAPPNR4A2BCHEMAOA | |
| SCHEMBL197223 | 0.91 | LMNA (0.67) | MAOBAPPNR4A2BCHEMAOA | |
| SCHEMBL27417060 | 0.91 | AR (0.58) | MAOBAPPNR4A2BCHEMAOA | |
| SCHEMBL10991891 | 0.89 | MAOB (0.80) | MAOBAPPNR4A2BCHEMAOA | |
| SCHEMBL850999 | 0.89 | APP (0.78) | MAOBAPPNR4A2BCHEMAOA | |
| SCHEMBL11846870 | 0.88 | BCHE (0.63) | MAOBAPPNR4A2BCHEMAOA | |
| SCHEMBL10609652 | 0.84 | LMNA (0.75) | MAOBAPPNR4A2BCHEMAOA | |
| SCHEMBL28999626 | 0.84 | NR4A2 (0.61) | MAOBNR4A2MAOA | |
| Benzylphenylether SCHEMBL61660 | 0.84 | LMNA (0.74) | MAOBAPPNR4A2BCHEMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979978-B1 | NONAQUEOUS ELECTROLYTE INCLUDING DIPHENYL ETHER AND LITHIUM SECONDARY BATTERY USING THEREOF | PANAX ETEC CO LTD (KR) | 2016-04-06 | — | — | EP | disclosed |
| US-20120283266-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2012-11-08 | — | — | US | disclosed |
| WO-2011035941-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2011-03-31 | — | — | WO | disclosed |
| US-7501510-B2 | Thiourea compositions and uses thereof | THE UNIVERSITY OF HONG KONG (CN) | 2009-03-10 | — | — | US | disclosed |
| CN-1304380-C | Benzo[a]henazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LTD (GB) | 2007-03-14 | — | — | CN | disclosed |
| US-20070043026-A1 | Dopamine receptor modulators as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1503989-A1 | DOPAMINE RECEPTOR MODULATORS AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003095428-A1 | DOPAMINE RECEPTOR MODULATORS AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2003-11-20 | — | — | WO | disclosed |
| CN-1433406-A | Benzo [ a ] phenazine-11-amide derivatives and their use as combined topoisomerase I and II inhibitors | XENOVA LTD (GB) | 2003-07-30 | — | — | CN | disclosed |
| EP-1240148-A1 | BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II | Xenova Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046157-A1 | BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II | XENOVA LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283266-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | JMJD6, KDM3A, KDM1A | MAOB 186/4885APP 4824/4885NR4A2 2756/4885 |
| US-20070043026-A1 | Dopamine receptor modulators as antipsychotic agents | SIGMAR1, CHRM1, OPRM1 | MAOB 291/4885APP 3231/4885NR4A2 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.